FDA to review Moderna mRNA flu vaccine on June 18

The FDA will convene an expert panel on June 18 to evaluate Moderna's mRNA-based flu vaccine. A final decision on the experimental shot is expected by August 5.

Xurve View
洞察:

The United States FDA will convene an expert panel to review the seasonal influenza vaccine from Moderna. The agency previously rejected the mRNA-based shot in February but reversed course after discussions with the company. A final approval decision is expected by August 5.

Overcoming the Initial Regulatory Rejection

IUX24

IUX24 提供深度財經、經濟與投資資訊,借助 AI 挖掘全球市場中最重要的訊號。

IFZA Properties, Dubai Silicon Oasis, DSO-IFZA, Dubai, United Arab Emirates

Copyright IUX24 MEDIA - FZCO. 版權所有。

由 AI 驅動 • 精益求精

IUX24 是一個資訊與分析平台,提供新聞、市場資料、分析工具及 AI 驅動的功能,僅供資訊參考與教育用途。所提供的服務和資訊不構成投資建議、交易訊號或經紀服務。投資涉及風險,使用者在做出投資決定前應審慎評估相關資訊。